Default company panoramic image
2add5918 c0dc 487f 8511 08412500d9e2

Idekos, Inc.

IDEKOS is dedicated to the development of products for diseases linked to an overexpression of TG2. The primary focus is Celiac Disease.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Los Altos, CA, USA
  • Currency USD

Company Summary

IDEKOS develops compounds that target TG2, the critical enzyme in the pathogenesis of the celiac disease. Several potent, small molecule inhibitors of TG2 from different chemical series have been identified. These molecules with composition of matter patents are a mix of reversible and irreversible inhibitors, show sub-micromolar to low nanomolar activity in BC assays and are selective to TG2. One has shown activity against the target in vivo.


  • Default avatar
    Bruno Delagneau

    Bruno has 20 years of management experience in the biotechnology and pharmaceutical industries at several diverse companies including Syntex, Roche, and Gilead among others. He is the founder of Idekos and a consultant to small to medium size companies as well as investment firms. He was also the founder of a small venture-backed start up dedicated to the development and commercialization of infectious disease products.
    Prior to founding his inf

  • Default avatar
    Amy Patick

    Amy has over 20 years of experience in preclinical research and development at companies such as BMS, Agouron, Pfizer and Genelabs. she is currently a scientific consultant to biotech and pharmaceutical companies and the CSO at Idekos.

  • Default avatar
    Richard Gless
    VP, Chemistry and manufacturing

    Richard has more than 25 years’ experience in medicinal, combinatorial and process chemistry at large companies such as Zeneca but also at small biotech companies including Arete Therapeutics, Galileo Pharmaceuticals and Signature Bioscience. He's currently a research and chemistry consultant to biotech companies and the VP, Chemistry and manufacturing at Idekos.